Publications and Posters

April 17, 2023
Prostate Cancer RIPTACTM Therapeutics Demonstrate Activity in Preclinical Models of Enzalutamide-Resistant Prostate Cancer

Presentation at American Association for Cancer Research (AACR) annual meeting demonstrates oral efficacy of RIPTAC therapeutics as a monotherapy for the treatment of prostate cancer.

February 16, 2023
An Oral RIPTACTM Therapeutic for Prostate Cancer

Presentation at American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium features preclinical data for a RIPTAC therapeutic candidate for the treatment of prostate cancer, demonstrating superior in vivo efficacy to standard of care agent in prostate cancer, enzalutamide.

January 2, 2023
Regulated Induced Proximity Targeting Chimeras (RIPTACs™): a Novel Heterobifunctional Small Molecule Therapeutic Strategy for Killing Cancer Cells Selectively

Halda has published a chemical biology demonstration of the RIPTAC therapeutic concept as a novel heterobifunctional drug modality to selectively treat cancers. The study establishes our novel approach with evidence of a hold and kill mechanism where a RIPTAC therapeutic kills cancer cells selectively by facilitating the formation of a neo protein-protein interaction interface between a tumor-specific protein and a pan-essential protein. Several chemical biology approaches were explored to exemplify mechanistic principles that are currently being applied to develop future RIPTAC therapeutics.


November 10, 2023
10 Startups to Watch
C&E News

March 13, 2023
Proximity-inducing drugs get closer
Nature Reviews Drug Discovery

June 23, 2021
Biotech Start-Up Halda Therapeutics Opens SciPark HQ
New Haven Independent

Back to Top